MA
ACHN

MUFG Americas’s Achillion Pharmaceuticals ACHN Stock Holding History

MUFG Americas’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-770
Closed -$7K – 1269
2015
Q2 		$7K Hold
770
– – ﹤0.01% 932
2015
Q1 		$8K Buy
770
+160
+26% +$2K ﹤0.01% 961
2014
Q4 		$7K Buy
+610
New +$7.45K ﹤0.01% 1049

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MUFG Americas's ACHN Position: Q3 2015 in Review

MUFG Americas sold out of Achillion Pharmaceuticals (ACHN) in Q3 2015, closing a stake of 770 shares — an estimated $7K sold.

MUFG Americas first reported a position in ACHN in Q4 2014 and held it in 3 quarters. The position peaked at $8K in Q1 2015. 141 funds tracked by Wall St. Rank hold ACHN as of Q3 2015.

  • MUFG Americas reported no remaining Achillion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • MUFG Americas sold 770 Achillion Pharmaceuticals shares in Q3 2015, an estimated $7K.
  • MUFG Americas first reported a position in Achillion Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • MUFG Americas's Achillion Pharmaceuticals position peaked at $8K in Q1 2015.
  • 141 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2015.

Based on MUFG Americas's 13F filing for Q3 2015, filed 10 Nov 2015.